U.S. President Biden and U.S. Senator Bernie Sanders stated in an article published in USA Today on July 2 that they plan to expand pharmaceutical price negotiations. The article states that the number of prescription drugs subject to price negotiations must be expanded to at least 50 per year, and they are jointly making efforts to develop relevant legislation. Prescription drug companies must also take action. The article states that Eli Lilly and Co. and Novo Nordisk A/S's diabetes treatments are too expensive. Novo Nordisk A/S must significantly lower the prices of Ozempic and Wegovy.